LPV 100mg / r 25mg, tab.
STD
DORALPVR4T-
Valid Article
Account code:
60000
HS Code:
300490
Last Updated on:
07/11/2024, 17:48:07
Former
Code(s):
-X DORALPRF1T2 DORAZBD0481 DORAZBD0482 DORAZFR0511 DORAZYN1057
6.4.2.3 - Protease inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AR10
Anatomical Therapeutic Chemical Classification according to WHOCC
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
LOPINAVIR (LPV) / RITONAVIR (r)
Therapeutic Action
Fixed-dose combination (FDC) of two antiretrovirals, protease inhibitors (PI)
Indications
HIV infection, in combination with other antiretrovirals
Instructions for use
Granules in sachet and 100mg/25mg tablets are intended for paediatric use.
Pour the granules into a small amount of breast milk, water or soft foods and administer immediately (within 2 hours of preparation max.).
Precautions for Use
Pellets-in-a-capsule and oral solutions became non-standard according to 2021 WHO list for antiretroviral drugs for children:
- granules in sachet can be given to children from the age of two weeks (instead of three months) and are easier to administer than pellets in capsule.
- with increasing use of integrase inhibitor–based regimens and a preference for granules, oral solution should no longer be required.
Storage
Below 25ºC - Protect from sunlight - Protect from humidity